China SXT Pharmaceuticals, Inc.
SXTCEarnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 1, 2026 | $14.00 | — | $1.2M | — |
| Oct 30, 2025 | $-823.00 | — | $626.6K | — |
| Nov 12, 2024 | $-99.00 | — | $414.7K | — |
| Jul 29, 2024 | $-99.00 | — | $414.7K | — |
| Oct 30, 2023 | $-967.00 | — | $898.2K | — |
| Jul 17, 2023 | $-967.00 | — | $469.8K | — |
| Jul 18, 2022 | $-730.00 | — | $604.1K | — |
| Mar 31, 2022 | $-2539.00 | — | $4.5M | — |
News
TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on October 26, 2026.
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termination letter agreement, the Company and the purchasers have terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement entered into in connection with…
New York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of $12 million for its client China SXT Pharmaceuticals Inc.
TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering. The Company also agreed to issue to the same…